News

Dual Cognitive, Motor Tasks More Difficult Even in Early MS Stages

Even in early stages of disease, people with multiple sclerosis (MS) commonly experience more difficulties performing cognitive and motor tasks simultaneously than do people without MS, a new study indicates. The study, “Cognitive-motor interference in people with mild to moderate multiple sclerosis, in comparison with healthy…

Pregnancy Risks Not Likely to Rise With Early DMT Use, Study Finds

The rates of pregnancy complications are not higher in women with multiple sclerosis (MS) who were using disease-modifying therapies (DMTs) in the earliest stages of pregnancy, a study reported. The study, “Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate or natalizumab in…

Robot-assisted Training for Arms Well-received by MS Patients

A robot-assisted training program that uses game-like activities to improve upper limb function was met with high satisfaction and enjoyment by people with multiple sclerosis (MS), a small study has found. Most of the participants reported the intervention improved their ability to do day-to-day activities, such as using a…

GA Depot Reduces Relapse Rates in Phase 3 Clinical Trial

Treatment with GA Depot, an experimental long-acting form of glatiramer acetate that requires less frequent dosing than approved formulations, significantly reduced relapse rates among people with relapsing forms of multiple sclerosis (MS), according to top-line results from a Phase 3 clinical trial. “We are pleased with the topline…

Second SPMS Patient Given Foralumab Continues to Improve

Six months of treatment with foralumab nasal spray led to significant functional improvements in the second patient with non-active secondary progressive multiple sclerosis (SPMS) who received treatment under a single-patient expanded access program. Findings from this patient have been generally consistent with those seen in the first non-active SPMS…

Prexasertib’s Protective Effects Seen in Models of Neurodegeneration

Prexasertib, a small molecule inhibitor that’s been tested in clinical trials for cancer, may represent a new strategy for treating multiple sclerosis (MS) and other neurodegenerative conditions, a study found. The compound, which inhibits the checkpoint kinase (Chk2) protein, was found to promote nerve cell survival and regeneration after…

Gut Bacteria Are Altered in MS, Linked to Disease Progression

The composition of bacteria in the gut is altered in multiple sclerosis (MS) patients compared with healthy people in the same household, a new study reports. That bacterial composition is affected by disease-modifying therapies and seems to be associated with disease severity. These findings could aid in developing…

Higher Levels of MS Fatigue Linked to Poorer Cognitive Skills

People with multiple sclerosis (MS) who report higher levels of fatigue are more likely to have lower performance scores in tests that evaluate cognitive skills, a study from Ireland suggests. Specifically, poor verbal learning abilities, visual-spatial memory, and information processing speed (IPS) were associated with higher levels of self-reported…

T-cells Targeting Epstein-Barr Virus at High Levels in MS Patients

People with multiple sclerosis (MS) have significantly more T-cells equipped with receptors that specifically recognize the Epstein-Barr virus (EBV) than do healthy individuals, a study revealed. Notably, no such differences were detected for T-cells with receptors specifically against other viruses. These findings add to previous data highlighting EBV infection…

Understanding MS Burden, Support Needs Can Challenge Couples

Differences are evident in the perceived frequency of expressions of support needs and disease burden between people with  multiple sclerosis (MS) and their life partners, a Swiss study found. People without MS responded in a survey to feeling their partners’ communication about these issues was more frequent than the…

Soft Inner Layer Surrounding Brain May Be MS Target, Study Finds

In multiple sclerosis (MS), disease-causing immune T-cells enter the brain and spinal cord through the protective soft membranes covering them, called the leptomeninges, a new study shows. The findings “suggest that patients with MS could benefit from immunomodulatory therapies that target the leptomeninges,” the researchers wrote, noting these surrounding…

Progression Without Relapse Also Common in RRMS, Patients Say

Nearly two-thirds of people with relapsing-remitting multiple sclerosis (RRMS) report disease progression independent of relapses, according to a survey involving more than 4,500 multiple sclerosis (MS) patients in Germany. This finding supports evidence pointing to progression independent of relapse activity (PIRA) as an underestimated contributing factor in RRMS.

Tysabri Improves Cognition Over Long-term in Early RRMS Patients

Long-term treatment with Tysabri (natalizumab) significantly improves cognitive function and increases the chance of disability reduction in people with early relapsing-remitting multiple sclerosis (RRMS), according to data from the four-year observational STRIVE trial. Patients on Tysabri also reported improved quality of life and less impact of MS on…

High-efficacy DMTs Boost Mid-term Prognosis for Relapsing MS: Study

People with relapsing multiple sclerosis (MS) treated with Tysabri (natalizumab) or Gilenya (fingolimod) are less likely to have disease activity than those on low-efficacy MS medications, according to a small study conducted in Japan. Results also showed that patients receiving the high-efficacy therapies had less brain shrinkage,…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here